Yu‐Li Su
Impact in
Papers in
- Co-authors
- Chun‐Chieh Huang (25 shared papers)Hao‐Lun Luo (27 shared papers)Kun-Ming Rau (14 shared papers)Po‐Hui Chiang (13 shared papers)Meng-Che Hsieh (13 shared papers)Ming‐Tse Sung (10 shared papers)Yen‐Yang Chen (7 shared papers)Ming-Yen Tsai (5 shared papers)
- Journals
- Frontiers in Oncology (6 papers)International Journal of Molecular Sciences (5 papers)Journal of Cancer (4 papers)The Lancet Oncology (3 papers)PLoS ONE (3 papers)
- Partner nations
- TaiwanUnited StatesChina
In The Last Decade
Yu‐Li Su
72 papers receiving 1.8k citations
Yu‐Li Su's Hit Papers
Peers
Comparison fields: 5 of 74
- Oncology 544
- Surgery 944
- Cancer Research 94
- Hepatology 38
- Pulmonary and Respiratory Medicine 126
Countries citing papers authored by Yu‐Li Su
This map shows the geographic impact of Yu‐Li Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yu‐Li Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yu‐Li Su more than expected).
Fields of papers citing papers by Yu‐Li Su
This network shows the impact of papers produced by Yu‐Li Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yu‐Li Su. The network helps show where Yu‐Li Su may publish in the future.
Co-authors
The 25 scholars most cited alongside Yu‐Li Su, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 79 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 490 |
| 2 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial Hit paper breakdown → | 2020 | 408 |
| 3 | 2017 | 141 | |
| 4 | 2019 | 73 | |
| 5 | 2016 | 40 | |
| 6 | 2020 | 34 | |
| 7 | 2013 | 31 | |
| 8 | 2022 | 31 | |
| 9 | 2018 | 28 | |
| 10 | 2019 | 28 | |
| 11 | 2019 | 27 | |
| 12 | 2018 | 25 | |
| 13 | 2015 | 24 | |
| 14 | 2015 | 21 | |
| 15 | 2020 | 19 | |
| 16 | 2022 | 19 | |
| 17 | 2023 | 18 | |
| 18 | 2021 | 17 | |
| 19 | 2023 | 16 | |
| 20 | 2019 | 15 |
About Yu‐Li Su
Yu‐Li Su is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Cancer Research and Hepatology, having authored 79 papers that have together received 1.8k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (29 papers), Colorectal Cancer Treatments and Studies (6 papers), Cancer Immunotherapy and Biomarkers (5 papers), Prostate Cancer Treatment and Research (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Inflammatory Biomarkers in Disease Prognosis (4 papers), Cancer Treatment and Pharmacology (3 papers) and Breast Cancer Treatment Studies (3 papers). The work is most often cited by research in Oncology (544 citations), Surgery (944 citations), Cancer Research (94 citations), Hepatology (38 citations) and Pulmonary and Respiratory Medicine (126 citations). Yu‐Li Su has collaborated with scholars based in Taiwan, United States and China. Frequent co-authors include Chun‐Chieh Huang, Hao‐Lun Luo, Kun-Ming Rau, Po‐Hui Chiang, Meng-Che Hsieh, Ming‐Tse Sung, Yen‐Yang Chen, Ming-Yen Tsai, Jei‐Ming Peng and Yung‐Hsiang Chen. Their work appears in journals such as Frontiers in Oncology, International Journal of Molecular Sciences, Journal of Cancer, The Lancet Oncology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.